Canaccord Genuity Capital Markets – Cognetivity Neurosciences Ltd.

Cognetivity Neurosciences Ltd. (CGN-CNSX) is a medical technology company. It has developed the Integrated Cognitive Assessment (ICA), a five-minute visual categorization task that uses natural images and AI to detect mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD) before the onset of memory symptoms. The prevalence of dementia is forecast to increase 166% globally by 2050. As a quick, low-cost tool that can be self-administered, the ICA has the potential to be used across primary care settings worldwide for preventative screening. Early detection could reduce the risk of progression and the resultant cost to the system. The ICA has been approved and is being commercialized as a diagnostic aid in the US, UK, Europe, and UAE. CGN expects to begin reporting revenue imminently and to turn FCF positive by late 2023. Insiders own ~25% of fully diluted shares, making them well-aligned with investors.